Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Up 156.9% in June

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a significant increase in short interest in June. As of June 30th, there was short interest totaling 455,197 shares, an increase of 156.9% from the June 15th total of 177,209 shares. Based on an average daily trading volume, of 444,373 shares, the days-to-cover ratio is currently 1.0 days. Currently, 46.8% of the shares of the stock are sold short.

Insiders Place Their Bets

In other Bluejay Diagnostics news, major shareholder Financial Lp Hrt purchased 64,047 shares of the stock in a transaction on Thursday, July 9th. The shares were purchased at an average price of $1.51 per share, with a total value of $96,710.97. Following the acquisition, the insider directly owned 126,993 shares in the company, valued at approximately $191,759.43. The trade was a 101.75% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 18.47% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Bluejay Diagnostics Price Performance

Shares of BJDX opened at $1.22 on Tuesday. Bluejay Diagnostics has a 1 year low of $1.03 and a 1 year high of $16.68. The stock has a 50 day simple moving average of $2.68 and a two-hundred day simple moving average of $2.48. The firm has a market cap of $1.26 million, a P/E ratio of -0.10 and a beta of 0.88.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.95) earnings per share for the quarter.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.